Clinical trial · Interventional
Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm
A Single-center, Prospective Randomized Controlled Study of Microwave Spherical Ablation and Traditional Microwave Ablation in the Treatment of Single Hepatocellular Carcinoma With a Diameter of ≤5cm
NCT05361538CI-TRIAL-00062682unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Cancer | Hepatocellular Carcinoma | CURATED_BROADER | 0.80 |
| Microwave Ablation | — | UNRESOLVED | — |
| Microwave Spherical Ablation | — | UNRESOLVED | — |
| Prognosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| True circular microwave needle | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MTA Group
- description
- Use true circular microwave needle for ultrasound-guided thermal ablation in MSA (microwave spherical ablation) group.
- interventionNames
- Device: True circular microwave needle
- type
- NO_INTERVENTION
- label
- MWA Group
- description
- Use normal microwave needle for ultrasound-guided thermal ablation in MTA (microwave ablation) group.
Primary outcomes (1)
- measure
- Comparison of progression-free survival between MSA and traditional MWA in HCC
- timeFrame
- 6 to 12 months
- description
- Compare the time to tumor progression after therapy of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5 cm
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient has high risk factors for HCC and was first diagnosed of HCC by by contrast-enhanced imaging (CECT/CEMRI/CEUS) and/or pathology ; 2. Age range 18 to 75 years old; 3. Single lesion with tumor diameter ≤5cm; 4. Patient refuses surgery and determines to undergo microwave ablation 5. Liver function Child Pugh A or B; 6. No extrahepatic metastasis or portal invasion; 7. Patient signs the informed consent. Exclusion Criteria: 1. The lesion has received treatment, including local ablation therapy and TACE therapy, etc; 2. With portal vein invasion or extrahepatic metastases; 3. Patient is with severe cardiopulmonary insufficiency. 4. Patient is a pregnant or breastfeeding women. 5. Patient is considered to be unsuitable to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.